Breaking News

Medivir, Daewoong Discontinue Hep B Alliance

September 6, 2013

MIV-210 fails to eradicate HBV

Medivir AB and Daewoong Pharmaceutical Co. Ltd. have decided to discontinue development of hepatitis B compound, MIV-210, based on a joint decision.
 
Under the collaboration Daewoong was responsible for R&D. While MIV-210 demonstrated competitive antiviral activity, like other drugs of this class, it did not completely eradicate HBV. Taking into consideration the commercial environment for HBV drugs, with the current standard of care approaching generic status, a robust cure profile is needed, which would require combination with other drugs.
 
“In light of the characteristics MIV-210 could offer for the treatment of Hepatitis B, we have together with our partner Daewoong decided to abandon the development activities with MIV-210”, said Maris Hartmanis, chief executive officer, Medivir AB.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers